Oct 162016

New study results from Austrian biotech AFFiRiS support continued development of its vaccine against the key Parkinson’s protein alpha-synuclein. Today the company announced its “boost” follow-up study— funded with a $1.04 million grant from The Michael J. Fox Foundation — showed that an additional dose is safe and can elicit antibodies against alpha-synuclein.

View Full Article

Author: Maggie McGuire Kuhl Publication: Fox Feed blog  Date: 09-07-2016

 Comments Off on Vaccine for Parkinson’s Reports Positive Results from Boost Study  Tagged with: ,
Sep 212016

We are excited to announce the approval of Eteplirsen (now renamed Exondys 51), the first drug that treats the underlying cause of Duchenne…
You Full Article

DV Note: September, 2016 the FDA gave contingent approval for the drug Exondys 51 to treat people with Duchenne Muscular Dystrophy (DMD) exon 51 abnormality. This will treat a percentage of people with DMD, but it is hopeful the drug could be modified to treat other exon abnormalities in DMD and possibly in other genetic disorders.

Additional Info 


Author: Catherine Jayasuriya  Publication: Coalition Duchenne  Date: 09-19-2016

 Comments Off on Contingent Approval of first Duchenne Muscular Dystrophy drug
Sep 042016

“By creating healthy muscle cells from the patient’s skin cells, the scientists avoid any risk of the cells being rejected by the patient’s immune system. Unlike traditional gene therapy, the faulty gene is corrected in cells outside the body”…

View Full Article


Author: Lussy Publication:  Healthline.Website  Date: 08-28-2016

Jul 222016

New York’s first medical marijuana dispensary opened in January, over a year after the state became the 23rd to legalize the drug for medical use and the fifth to approve Parkinson’s disease (PD) as a condition for its use. This news understandably led the patient and physician communities to ask a number of research and clinical questions about marijuana and Parkinson’s.

View Full Article


Author: Rachel Dolhun, MD Publication: Michael J Fox Foundation Foxfeed Date: 02-01-2016 

May 242016

Motor fluctuations are “off” times, when medication — namely levodopa (the “gold standard” treatment for Parkinson’s) — is not working optimally and Parkinson’s symptoms …

View Full Article

Author: Rachel Dolhun, MD Publication: The Michael J Fox Foundation FOXFEED Blog Date: 05-23-2016


 Comments Off on “Off” Time in Parkinson’s Disease
Apr 282016

On Monday, April 25 the Muscular Dystrophy Association (MDA) along with MDA clinical experts testified before an FDA advisory committee. They express optimism for this new drug, eteplirsen, helping people with Duchenne Muscular Dystrophy (DMD) and it opening doors for treating more genetic disorders. Eteplirsen is an Exxon shipping drug which is designed to skip certain parts of defective genes to allow the genes to still express a protein. In DMD this drug therapy would basically turn DMD into a mild form of Backers Muscular Dystrophy. Backers Muscular Dystrophy is already much more mild than Duchenne Muscular Dystrophy. This treatment would help thousands of people live a healthier and longer life.
View Full Article
Publication: MDA Outreach Date: 04-25-2016

3 Videos Below 


 Comments Off on Eteplirsen FDA Hearings – MDA Testimony
Jan 072016

Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice.

View Full Article
ublication: Sourced Publication:UT Southwestern Medical Center Date: 1-4-16

 Comments Off on Gene-editing technique successfully stops progression of Duchenne muscular dystrophy
Jan 022016

Brooklyn Brumfield was 16 when she was given a grim prognosis.

She would likely spend the rest of her life in treatment and would need physical therapy.

View Full Article
Author: Nora Olabi Publication: msn.com Sourced Publication: Houston Chronicle

Date: 12-25-15

 Comments Off on Woodlands teen overcomes rare disease to walk again